Physician profile
Edward Katz
NPI 1568591345
$15,094.88
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,330 · 2020: $2,095 · 2021: $2,695 · 2022: $2,625 · 2023: $2,605 · 2024: $1,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,225 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,225.43 |
| Education | $125.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,301.62 | 2019-2024 | |
| Amgen INC. | $1,727.55 | 2019-2024 | Prolia, Evenity, Enbrel |
| Pfizer INC. | $1,527.87 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $1,429.93 | 2019-2024 | |
| Janssen Biotech, INC. | $1,395.63 | 2019-2024 | Tremfya, Remicade, Simponi Aria |
| Lilly USA, LLC | $1,075.64 | 2019-2024 | Taltz |
| Mallinckrodt Enterprises LLC | $766.21 | 2019 | |
| Ani Pharmaceuticals, INC. | $628.09 | 2022-2024 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $617.28 | 2019-2024 | Benlysta, Nucala |
| Ucb, INC. | $575.03 | 2019-2024 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $433.82 | 2020-2024 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $382.19 | 2019-2024 | Orencia |
| Fresenius Kabi USA, LLC | $249.40 | 2023-2024 | Idacio |
| Sandoz INC. | $154.47 | 2023-2024 | Hyrimoz |
| Genzyme Corporation | $147.99 | 2020-2024 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.